Medicare Response To ESA "Overuse" In CKD Will Await Impact Of Bundled Payments, CMS Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Final CMS decision confirms proposal to withhold a national Medicare coverage policy for erythropoiesis stimulating agents in chronic kidney disease.
You may also be interested in...
Medicare Proposes Changes To Target Hemoglobin Levels In ESRD Treatment
CMS aims at “retiring” the floor hemoglobin level of 10 g/dL and lowering the target upper level to 11 g/dL in its proposed rule for the Medicare Part B prospective payment system for treatment of end-stage renal disease, a move that could apply more pressure to Amgen’s erythropoiesis-stimulating agents franchise.
Medicare Proposes Changes To Target Hemoglobin Levels In ESRD Treatment
CMS aims at “retiring” the floor hemoglobin level of 10 g/dL and lowering the target upper level to 11 g/dL in its proposed rule for the Medicare Part B prospective payment system for treatment of end-stage renal disease, a move that could apply more pressure to Amgen’s erythropoiesis-stimulating agents franchise.
Epogen Facing Sales Hit With Reduced Dosing Instructions In ESA Labeling For Renal Disease
Amgen agrees to studies to find what FDA calls "better, safer dose regimen strategies" as ESA labeling revisions create more conservative dosing guidelines for the products.